Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD by Böcskei, Renáta et al.
Vol.:(0123456789) 
Lung (2019) 197:189–197 
https://doi.org/10.1007/s00408-019-00211-w
COPD
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial 
Stiffness in Patients with COPD
Renáta M. Böcskei1  · Béla Benczúr2 · György Losonczy1  · Miklós Illyés3 · Attila Cziráki3 · Veronika Müller1  · 
Anikó Bohács1 · András Bikov1 
Received: 15 December 2018 / Accepted: 18 February 2019 / Published online: 28 February 2019 
© The Author(s) 2019
Abstract
Introduction Soluble urokinase-type plasminogen activator receptor (suPAR) is upregulated by inflammation and plays a 
role in the pathogenesis of atherosclerosis. Chronic obstructive pulmonary disease (COPD) is associated with enhanced 
systemic inflammation and increased risk for atherosclerosis, however, studies analysing the circulating suPAR levels in 
COPD are contradictory. The aim of the study was to investigate plasma suPAR concentrations together with markers of 
arterial stiffness in COPD.
Materials and Methods Twenty-four patients with COPD and 18 non-COPD, control subjects participated in the study. 
Plasma suPAR was measured, together with lung volumes, symptom burden, exacerbation history, markers of arterial stiffness 
and soluble inflammatory biomarkers, such as endothelin-1, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6).
Results Plasma suPAR levels were higher in COPD (2.84 ± 0.67 ng/ml vs. 2.41 ± 0.57 ng/ml, p = 0.03) and were related 
to lung function measured with  FEV1 (r = − 0.65, p < 0.01) and symptom burden determined with the modified Medical 
Research Council questionnaire (r = 0.55, p < 0.05). Plasma suPAR concentrations correlated with various measures of arte-
rial stiffness in all subjects, but only with ejection duration in COPD (r = − 0.44, p = 0.03).
Conclusions Plasma suPAR levels are elevated in COPD and relate to arterial stiffness. Our results suggest that suPAR may 
be a potential link between COPD and atherosclerosis.
Keywords COPD · SuPAR · IL-6 · Arterial stiffness · Cardiovascular risk
Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic, 
progressive disorder of the airways and lung parenchyma 
and is one of the leading causes of mortality worldwide 
[1]. Chronic exposure to noxious particles, especially to 
smoking induces airway inflammation which eventually 
leads to mucus hypersecretion, emphysema and small airway 
narrowing [2]. COPD is also associated with small-grade 
systemic inflammation which may be a potential link to car-
diovascular comorbidities, such as atherosclerosis [3–5]. 
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However, the elements of systemic inflammation are poorly 
described in COPD.
Soluble urokinase-type plasminogen activator receptor 
(suPAR) is a soluble form of the urokinase plasminogen 
activator receptor (uPAR) that is produced upon cleavage 
of membrane-bound uPAR. It is found in various body flu-
ids, including blood, urine and cerebrospinal fluid [6–8]. It 
is expressed by endothelial cells, macrophages, monocytes, 
neutrophils, lymphocytes and fibroblasts [9], and is upregu-
lated by infections and pro-inflammatory cytokines [6]. The 
suPAR contributes to plasminogen activation, cell adhesion, 
chemotaxis and immune cell activation [10]. Clinical studies 
suggest that suPAR has an additive value to high-sensitivity 
C-reactive protein (hsCRP) or interleukin-6 (IL-6) in char-
acterizing systemic inflammation in cardiovascular diseases 
[11].
So far, only few studies have investigated suPAR in 
COPD, mainly focusing on acute exacerbations and report-
ing elevated levels [12, 13]. In stable disease, Can et al. 
reported higher serum suPAR levels compared to controls 
[14]. This contradicts a study by Wang et al. who did not find 
significant difference between COPD and those in a healthy 
condition [15]. The discrepancy may be due to the relatively 
mild disease severity of the latter study [15], as the former 
study assessed patients with a wider range of lung function 
[14]. In addition, a number of factors which characterize 
disease burden apart from lung function, including symptom 
burden, exacerbation history and arterial stiffness, has not 
been assessed.
The aim of the present study was, therefore, to compare 
circulating suPAR levels in COPD and health, and to cor-
relate them with various characteristics of COPD. To study 
suPAR in the context of other inflammatory biomarkers we 
also analysed hsCRP, IL-6 and endothelin-1.
Materials and Methods
Study subjects
A total of 42 middle aged individuals (n = 19 males, mean 
age: 59 ± 11 years), were included in the study. Figure 1 dis-
plays the enrolment of participants into the study. COPD 
patients (n = 24) were recruited at stable state at the outpa-
tient clinic of the Department of Pulmonology, Semmelweis 
University. COPD was diagnosed according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
criteria based on symptoms, suggestive history and post-
bronchodilator  FEV1/FVC < 0.70 [1]. Patients were catego-
rised into ABCD subgroups according to the 2017 GOLD 
criteria [1]. Exacerbations in the last 12 months were defined 
as episodes requiring an increase in inhaler use or need for 
addition of antibiotics and/or systemic steroids. Frequent 
exacerbator phenotype was defined as having ≥ 2 exacer-
bations last year. None of the patients had suffered from 
acute exacerbation in the last 3 months. Control volunteers 
(n = 18) were recruited among co-workers at the Depart-
ment of Pulmonology. Subjects with known cardiovascular 
disease, including coronary artery disease, cerebrovascular 
disease, or peripheral arterial disease and those who had dia-
betes mellitus were excluded. None of the study participants 
had an ongoing infection during the study.
Study Design
The study had a case–control, cross-sectional design. After 
obtaining written informed consent, medical history was 
taken, patients filled out the COPD Assessment Test (CAT) 
and modified Medical Research Council (mMRC) ques-
tionnaires, body plethysmography and arteriography were 
Fig. 1  Flow chart of the number 
and selection of individuals in 
the study population
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performed and arterialised capillary blood gases were meas-
ured. Venous blood was taken for total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglyceride, hsCRP, IL-6, 
endothelin-1 and suPAR measurements.
The study has been approved by the Semmelweis Univer-
sity Ethics Committee (TUKEB 131/2017), and all partici-
pants gave their informed consent.
Body Plethysmography
Lung function tests and body plethysmography were carried 
out with the PDD-301/s device (Piston Ltd., Budapest, Hun-
gary) according to the American Thoracic Society guide-
lines [16]. Lung function indices were calculated using the 
best of three technically acceptable measurements.
Measurement of Arterial Stiffness and Blood 
Pressure
Blood pressure parameters and arterial stiffness parameters, 
including aortic pulse wave velocity (PWVao) and Aortic 
Augmentation Index (Aix) measurements were performed 
in the supine position and after 10 min of rest using an inva-
sively validated oscillometric, upper-arm cuff automatic 
device based on the ‘occluded artery theory’ (Arteriograph, 
TensioMed Ltd., Budapest, Hungary). Details of the method 
and its invasive validations have been published previously 
[17, 18]. In brief, the device first measures the actual bra-
chial systolic blood pressure (SBPbr) and brachial diastolic 
blood pressure (DBP) with a clinically validated algorithm 
[19]. The cuff is then inflated to a supra-systolic pressure 
(35–40 mmHg above the actual brachial systolic blood pres-
sure) occluding the brachial artery completely. Pure pres-
sure signals are collected by the cuff in this condition. The 
time difference between the early and late systolic peaks, is 
the return time (RT). By dividing the return time by 2, the 
transit time of the aortic pulse wave is obtained. By measur-
ing the jugulum to symphysis straight distance between the 
suprasternal notch and pubic bone (an acceptable estimate of 
the aortic length [20]), divided by transit time, the PWVao 
(m/s) can be calculated. The Augmentation Index (Aix) was 
calculated taking the differences between amplitudes of the 
forward and reflected systolic waves. The left ventricle ejec-
tion duration (ED) is calculated from the pulse waves, by 
measuring the time between the opening and closing of the 
aortic valve. The Arteriograph calculates the central blood 
pressure (SBPao) based on the brachial SBPbr and the pulse 
pressure curve. SBPao is the systolic blood pressure meas-
ured at the aortic root. The difference between the central 
and peripheral systolic pressure (SBPao–SBPbr) is called 
pressure amplification. At younger ages when the aortic wall 
is still elastic the SBPao is less than SBPbr on the upper arm.
Circulating Biomarkers
Plasma was isolated from EDTA anticoagulated fasting 
blood samples and stored at − 80 °C until measurement. 
Plasma suPAR concentrations were measured with the 
suPARnostic Flex ELISA assay (ViroGates A/S, Birkerød, 
Denmark) according to the manufacturers’ instructions. 
Interleukin-6 levels were analysed by the Immulite 2000 
immunoassay system (Siemens Healthcare GmbH, Erlan-
gen, Germany). Plasma endothelin-1 levels were determined 
with the Endothelin (1–21) ELISA Kit (Biomedica, Mediz-
inprodukte GmbH & Co KG, Wien). The hsCRP levels were 
measured using commercially available tests (Roche Diag-
nostics GmbH, Mannheim, Germany). The technicians who 
measured the samples were blinded to the identity of the 
patient samples.
Statistical Analysis
GraphPad Prism 5.03 (GraphPad Software, La Jolla, CA, 
US) was used for statistical analysis. Data normality has 
been assessed with the Shapiro–Wilk test. COPD and control 
groups were compared with un-paired t test, Mann–Whit-
ney and Chi square tests. The relationships between plasma 
suPAR levels and clinical variables as well as circulating 
biomarkers were assessed with Pearson’s and Spearman’s 
tests. Data are expressed as mean ± standard deviation for 
parametric and median/range/for non-parametric variables. 
A p value < 0.05 was considered significant.
The sample size was calculated to find a difference 
between COPD and control group with an effect size of 
0.90, power of 0.80 and an alpha of 0.05 [21]. These num-
bers were based on a distribution of plasma suPAR values 
[22]. Post hoc sensitivity analyses ensured it was possible to 
detect correlations between suPAR and clinical variables as 
well as other plasma biomarkers with an effect size of 0.54 
(− 0.40 and 0.40, minimal and maximal critical r values), 
statistical power of 0.80 and alpha of 0.05 [21].
Results
Comparison of COPD and Control Groups as Well 
as Ever‑ and Never‑Smoker Controls
Characteristics of the study population are presented in 
Table 1. The levels of plasma suPAR were significantly 
higher in patients with COPD (2.84 ± 0.67  ng/ml vs. 
2.41 ± 0.57 ng/ml, p = 0.03, Fig. 2).
Ever-smoker controls (n = 9) tended to have elevated 
plasma suPAR levels, and significantly increased PWVao 
as well as decreased RT,  FEV1 and FVC compared to never-
smokers. Comparison of smoker and non-smoker controls 
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is presented in Table 2. There was a significant correlation 
between cigarette pack years and plasma suPAR levels in 
controls (r = 0.68, p < 0.01).
Relationship Between Circulating suPAR 
and Measures of COPD Severity and Activity
There was a significant relationship between circulating 
suPAR levels and  FEV1% (r = − 0.65, p < 0.01, Fig. 3), 
 FEV1/FVC (r = − 0.46, p = 0.02) and mMRC (r = 0.55, 
p < 0.01, Fig. 4). In addition, plasma suPAR levels tended 
to be elevated in patients with frequent exacerbations 
(3.09 ± 0.39 ng/ml vs. 2.58 ± 0.79 ng/ml, p = 0.058). In 
Table 1  Subjects’ 
characteristics
Data are expressed as mean ± standard deviation or median/range/or percentage. Significant differences are 
highlighted in bold
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1  s, FVC forced vital 
capacity, RV residual volume, TLC total lung capacity, Raw airway resistance, CAT COPD Assessment 
Test, mMRC Modified Medical Research Council Dyspnea Scale, HDL-C high-density lipoprotein choles-
terol, LDL low-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, IL-6 interleu-
kin-6, suPAR soluble urokinase-type plasminogen activator receptor, ED-1 endothelin-1
COPD (n = 24) Controls (n = 18) p value
Age (years) 60.9 ± 5.3 58.4 ± 6.5 0.16
Gender (males%) 54% 33% 0.18
Smoker (ever/never) 23/1 9/9 < 0.01
Smoker (current/ex/never) 9/14/1 8/1/9 < 0.01
Cigarette pack years 33.9 ± 18.2 11.4 ± 15.2 < 0.01
Number of frequent exacerbators 12 NA NA
FEV1 (l) 1.43 ± 0.67 2.81 ± 0.67 < 0.01
FEV1 (% pred.) 47.8 ± 22.4 101 ± 19.9 < 0.01
FVC (l) 2.7 ± 0.83 3.6 ± 0.9 < 0.01
FVC (% pred.) 69.7 ± 23.3 107.6 ± 18.2 < 0.01
FEV1/FVC (%) 51.9 ± 12.7 78.2 ± 3.9 < 0.01
RV (l) 4.2 ± 1.6 2.2 ± 0.8 < 0.01
TLC (l) 7.3 ± 1.8 5.9 ± 1.6 0.018
RV/TLC (%) 57.3 ± 11.9 36.7 ± 8.4 < 0.01
Raw (kPa*s/l) 0.48 ± 0.2 0.28 ± 0.1 < 0.01
pO2 (mmHg) 65.1 ± 7.4 76.8 ± 8.1 < 0.01
pCO2 (mmHg) 41.1 ± 4.7 38.9 ± 2.7 0.13
CAT 18.5 ± 7.2 7.8 ± 2.7 < 0.01
mMRC 1.8 ± 0.8 0.2 ± 0.4 < 0.01
Total cholesterol (mmol/l) 5.4 ± 0.8 5.1 ± 0.8 0.42
Triglyceride (mmol/l) 1.3 ± 1.0 1.9 ± 1.5 0.18
HDL-C (mmol/l) 1.7 ± 0.3 1.4 ± 0.25 0.04
LDL-C (mmol/l) 2.9 ± 1.0 3.0 ± 0.5 0.67
hsCRP (mg/l) 2.50 /0.50–7.80/ 1.65 /0.5–4.9/ 0.14
IL-6 (pg/ml) 4.29 /2.61–13.63/ 3.47 /1.65–5.75/ 0.03
suPAR (ng/ml) 2.8 ± 0.7 2.4 ± 0.6 0.03
ED-1 (fmol/ml) 1.3/0.0–10.1/ 0.8/0.0–6.1/ 0.18
Fig. 2  Plasma suPAR levels in COPD and controls. Significantly 
higher plasma suPAR levels were detected in COPD (*p = 0.03). Indi-
vidual data are presented with mean ± standard deviation
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Table 2  Comparison of ever- 
and never-smokers
Data are expressed as mean ± standard deviation or median /range/or percentage. Significant differences are 
highlighted in bold
FEV1 forced expiratory volume in 1  s, FVC forced vital capacity, RV residual volume, TLC total lung 
capacity, Raw: airway resistance, hsCRP high sensitivity C-reactive protein, IL-6 interleukin-6, suPAR 
soluble urokinase-type plasminogen activator receptor, ED-1 endothelin-1, SBPbr brachial systolic blood 
pressure, DBP brachial diastolic blood pressure, HR heart rate, PP pulse pressure, SBPao the central blood 
pressure, SBPao SBPbr pressure amplification, Aix Augmentation Index, ED ejection duration, PWVao aor-
tic pulse wave velocity, RT return time
Control
Never-smoker (n = 9)
Control
Ever-smoker (n = 9)
p value
FEV1 (l) 3.1 ± 0.68 2.5 ± 0.54 0.05
FEV1 (% pred.) 103.8 ± 21.5 99.3 ± 19.9 0.28
FVC (l) 4.1 ± 0.9 3.2 ± 0.7 0.02
FVC (% pred.) 112.3 ± 19.1 102.9 ± 17.0 0.3
FEV1/FVC (%) 76.8 ± 3.8 79.6 ± 3.7 0.13
RV (l) 2.56 ± 0.9 1.9 ± 0.67 0.17
TLC (l) 6.8 ± 1.8 5.1 ± 0.8 0.11
RV/TLC (%) 37.1 ± 6.3 36.4 ± 10.22 0.74
Raw (kPa*s/l) 0.26 ± 0.8 0.31 ± 0.4 0.27
hsCRP (mg/l) 1.4/0.50–3.8/ 1.9/0.7–4.9/ 0.18
IL-6 (pg/ml) 3.3/2.55–4.13/ 3.7/1.65–5.75/ 0.29
suPAR (ng/ml) 2.1 ± 0.5 2.7 ± 0.5 0.08
ED-1 (fmol/ml) 0.29/0.0–3.1/ 1.17/0.3–6.1/ 0.11
SBPbr (mmHg) 129 ± 11.1 131 ± 8.4 0.76
DBP (mmHg) 78 ± 8.6 76 ± 6.4 0.71
HR (min) 67 ± 8.6 71 ± 17.8 0.52
PP (mmHg) 51.1 ± 6.9 52.0 ± 6.1 0.78
SBPao (mmHg) 122/98–142/ 129/113–148/ 0.71
SBPao–SBPbr (mmHg) − 5/− 10 to 2/ − 1.1/− 11 to 7/ 0.18
Aix% − 12.2 ± 23.6 − 2.6 ± 33.0 0.49
ED (ms) 320.0 ± 25.9 321.1 ± 33.1 0.94
PWVao (m/s) 8.1 ± 0.9 9.5 ± 1.3 0.03
RT (ms) 127.7 ± 15.8 102.7 ± 16.3 < 0.01
Fig. 3  Relationship between plasma suPAR levels and lung function. 
A significant relationship was detected between plasma suPAR levels 
and  FEV1 (r = − 0.65, p < 0.01)
Fig. 4  Relationship between plasma suPAR levels and symptoms bur-
den. A significant relationship was detected between plasma suPAR 
levels and mMRC score (r = 0.55, p < 0.01)
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contrast, there was no relationship between plasma suPAR 
levels and FVC,  pO2,  pCO2, Raw, RV, TLC, RV/TLC or CAT 
(all p > 0.05).
Relationship Between Circulating suPAR 
and Markers of Arterial Stiffness
Comparison of the two groups in terms of arterial stiffness 
is found in Table 3. There was a significant difference in 
SBPao, SBPao–SBPbr, PWVao and RT (all p < 0.05), sug-
gesting increased arterial stiffness in COPD.
When all subjects were investigated together, a signifi-
cant correlation was seen between plasma suPAR concen-
trations and ejection duration (r = − 0.31, p = 0.04), PWVao 
(r = 0.38, p = 0.01) and RT (r = − 0.31, p = 0.04), but there 
was no correlation with Aix%, PP or SBPao (all p > 0.05).
When only the COPD subjects were analysed, only 
ejection duration correlated with plasma suPAR levels 
(r = − 0.44, p = 0.03).
Relationship Between Circulating suPAR and IL‑6, 
Endothelin and hsCRP
There was a significant direct relationship between circu-
lating suPAR concentrations and IL-6 (r = 0.45, p < 0.01), 
hsCRP (r = 0.47, p < 0.01) and endothelin-1 (r = 0.48, 
p < 0.01) levels in all subjects. When the COPD subjects 
were analysed separately, plasma suPAR related to hsCRP 
(r = 0.53, p < 0.01) and endothelin (r = 0.54, p < 0.01) and 
tended to be related to IL-6 (r = 0.40, p = 0.051).
Discussion
We investigated the plasma levels of suPAR, a novel bio-
marker of inflammation in COPD. We found elevated levels 
in COPD which correlated with lung function and symptom 
burden. A significant association was also found between 
increased suPAR levels and arterial stiffness, suggesting that 
this molecule may play a role in development of atheroscle-
rosis in COPD.
The prevalence of cardiovascular comorbidities [23], 
including atherosclerosis [24] is high in COPD, and COPD 
is also prevalent in patients with known atherosclerosis [25]. 
Arterial stiffness is not only a marker of clinically sympto-
matic disease, but preclinical atherosclerosis as well. Recent 
meta-analysis reported impaired endothelial function, a sur-
rogate for arterial stiffness in COPD [26]. This has been 
confirmed by our study reporting increased arterial stiffness 
in patients with COPD. The pathomechanism linking COPD 
to atherosclerosis is complex and includes common risk fac-
tors, such as smoking, pollution, male gender, and aging and 
systemic inflammation [24]. Pro-inflammatory cytokines, 
such as IL-6 or TNF-α are elevated in blood samples of 
COPD patients and can induce the release of CRP and pro-
coagulant mediators by the liver, but have also a direct effect 
on endothelium [24]. IL-6 and TNF-α can also induce the 
production of suPAR from monocytes and lymphocytes [27], 
which has a well-established role in the development of 
atherosclerosis [28]. It induces cellular adhesion, leukocyte 
migration and eventually leads to the formation of an ath-
erosclerotic plaque [29, 30]. Previous studies revealed that 
increased plasma suPAR levels were associated with risks 
for subclinical carotid atherosclerosis and increased occur-
rence of carotid plaque and cardiovascular disease [31, 32]. 
The prognostic value was independent from traditional risk 
factors (i.e., age, gender, smoking, hypertension, dyslipi-
demia, diabetes), and hsCRP [33, 34]. Moreover, the Moni-
toring Trends and Determinants in Cardiovascular Disease 
study compared suPAR with CRP and showed that suPAR is 
more related to endothelial dysfunction and atherosclerosis 
than CRP [35].
Circulating suPAR levels have been determined in COPD 
only by a few studies [12–15]. Two studies analysed suPAR 
during acute exacerbations [12, 13]. These events are asso-
ciated with airway and systemic inflammatory responses, 
and not surprisingly elevated suPAR levels were found dur-
ing exacerbations [12, 13]. The results in stable disease are 
contradictory, as both higher [14] and similar [15] levels 
were found. Comparing the two studies, the most striking 
difference was observed in the severity of airflow limitation, 
as Wang et al. recruited participants with milder severity 
[15]. However, large COPD studies, such as COPDGene 
or ECLIPSE confirmed a significant relationship between 
Table 3  Comparison of measures of blood pressure and arterial stiff-
ness between COPD and controls
Data are expressed as mean ± standard deviation or median /range/or 
percentage. Significant differences are highlighted in bold
SBPbr brachial systolic blood pressure, DBP brachial diastolic blood 
pressure, HR heart rate, PP pulse pressure, SBPao the central blood 
pressure, SBPao–SBPbr pressure amplification, Aix Augmentation 
Index, ED ejection duration, PWVao aortic pulse wave velocity, RT 
return time
COPD (n = 24) Controls (n = 18) p value
SBPbr (mmHg) 135 ± 12.4 130 ± 9.6 0.18
DBP (mmHg) 85 ± 10.9 77 ± 7.3 0.02
HR (min) 72 ± 16 69 ± 13.7 0.59
PP (mmHg) 53.5 ± 10.5 51.6 ± 6.4 0.50
SBPao (mmHg) 143/106–156/ 123/98–148/ < 0.01
SBPao–SBPbr (mmHg) 4/− 16 to 11/ − 4/− 11 to 7/ < 0.01
Aix% 10.1 ± 30.6 − 7.4 ± 20.3 0.06
ED (ms) 308.5 ± 36.5 320.6 ± 28.7 0.25
PWVao (m/s) 10.6 ± 1.9 8.8 ± 1.3 < 0.01
RT (ms) 99.6 ± 20.6 115.2 ± 20.2 < 0.01
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the extent of airflow limitation and magnitude of systemic 
inflammation [36]. We included patients with a wide range 
of lung function and found a significant relationship between 
airflow limitation and higher suPAR levels.
The most likely explanation of increased suPAR levels 
in COPD is the increase in IL-6 which is in line with the 
literature [37]. IL-6 upregulates suPAR production [27] 
which was supported by a significant association between 
these two molecules in our study. Circulating IL-6 induces 
the endothelium to release chemotactic factors for leuko-
cytes and adhesion molecules [24], and high blood levels 
are associated with cardiovascular comorbidities in COPD 
[38]. SuPAR which is also induced by IL-6, have more direct 
effect in formation of the atherosclerotic plaques [29, 30], 
and therefore, may be a more specific biomarker of endothe-
lial dysfunction in COPD than other circulating mediators. 
The clinical role of using suPAR as a biomarker for cardio-
vascular disease has already been assessed [11]. The current 
study implies that this molecule can also be useful in COPD 
and associated atherosclerosis, however, this has to be con-
firmed in larger cohorts.
Apart from lung function, suPAR was associated with 
symptom burden measured by the Mmrc in which score 
reflects breathlessness in relation to physical exercise. It 
is likely that this association is not independent from lung 
function, but due to the low number of subjects we did not 
test this. There was a tendency for higher plasma suPAR 
levels in patients with frequent exacerbations. This is in line 
with the findings of the ECLIPSE cohort that persistent sys-
temic inflammation is related to the frequency of exacerba-
tions [39]. The predictive value of suPAR to detect patients 
with higher risk for exacerbation has to be assessed in inde-
pendent cohorts. Interestingly, we did not find any associa-
tion between plasma suPAR levels and blood gases, sug-
gesting that hypoxia may not be a strong signal for suPAR 
production, however, this has to be tested as well.
The biggest limitation of our study was a relatively low 
sample size. This was based on our previous study using 
the same medium (EDTA-treated plasma samples) and 
analytical technique [22]. This sample size allowed us to 
explore univariate relationships between suPAR and clinical 
variables, however, to conclude on independency of these 
association, a higher sample size is warranted. A significant 
relationship was found between plasma suPAR concentra-
tions and markers of arterial stiffness when all subjects were 
investigated, however, many of these correlations disap-
peared when only the COPD patients were studied. A pos-
sible explanation could be the low sample size, but more 
likely it is due to the relatively mild extent of atheroscle-
rosis in these patients as we excluded those patients with a 
manifesting cardiovascular disease. Ejection duration was 
the only variable which remained significantly associated 
with plasma suPAR in COPD. Increased arterial stiffness 
decreases systolic ejection duration which is associated with 
impaired coronary blood flow, therefore, ED serves as an 
important biomarker for development of coronary artery 
disease [40]. The reason why suPAR correlated with this 
and no other markers of arterial stiffness has to be explored 
in further studies.
The control groups included ever and never-smoker 
participants. Previous studies reported higher circulating 
suPAR levels in smokers [41, 42] which was confirmed in 
this study. There were significant differences in the preva-
lence of smokers and smoking history between the COPD 
and control groups, and ever-smoker controls had lower lung 
function volumes and elevated markers of arterial stiffness. 
The inter-group difference in suPAR may partially result 
from smoking. Future studies should aim for control groups 
with a more balanced smoking history.
Conclusion
In summary, we reported higher plasma suPAR levels in 
COPD, which are associated with impaired lung function 
and increased arterial stiffness. Plasma suPAR may be a 
potential link between COPD and cardiovascular comorbidi-
ties, however, this and its potential biomarker role have to be 
investigated in further studies.
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